MedTrace Logo

Topical Aluminium Chloride vs OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs)

NCT03433859 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2021-04-28

No results posted yet for this study

Summary

The aim of this study is to demonstrate onabotulinumtoxinA superiority to aluminium chloride for the treatment of residual limb hyperhidrosis.

Conditions

  • Hyperhidrosis
  • Residual Limbs

Interventions

DRUG

OnabotulinumtoxinA

OnabotulinumtoxinA in intradermal Injections on residual lower limb : 100 Units - 1 dose

OTHER

Topical Aluminium Chloride (cosmetic product)

Topical Aluminium Chloride (cosmetic product) : 1 quantity sufficient on the lower limb

Sponsors & Collaborators

  • Direction Centrale du Service de Santé des Armées

    lead OTHER

Principal Investigators

  • Hélène BISSERIEX, MD · Service de Santé des Armées, Hôpital Clermont-Tonnerre (Brest, France)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2020-09-10
Completion
2021-03-03

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03433859 on ClinicalTrials.gov